Increased vaccine tolerability and protection via NF-κB modulation.

Area of Science:

• Vaccinology
• Immunology
• Molecular Biology

Background:

• Adjuvant development aims to improve vaccine efficacy but faces challenges in balancing immune activation with inflammatory side effects.
• Current adjuvants lack the ability to independently modulate inflammatory responses and protective immunity.
• Nuclear factor kappa B (NF-kB) signaling plays a critical role in both inflammation and adaptive immunity.

Purpose of the Study:

• To develop a novel vaccine strategy that limits inflammation while enhancing protective immune responses.
• To investigate the efficacy of combining a partial selective NF-kB inhibitor with existing adjuvants.
• To assess the broad applicability of this approach across different adjuvants and antigens.

Main Methods:

• A partial selective NF-kB inhibitor was combined with various conventional vaccine adjuvants.
• The resulting vaccine formulations were tested for their ability to modulate systemic inflammation.
• Protective immune responses and efficacy were evaluated using an influenza challenge model.

Main Results:

• Vaccine formulations incorporating the NF-kB inhibitor demonstrated reduced systemic inflammation.
• These formulations maintained or increased protective immune responses compared to conventional adjuvants alone.
• Enhanced protection was observed in the influenza challenge model, validating the approach.

Conclusions:

• Combining a partial selective NF-kB inhibitor with current adjuvants offers a viable strategy to mitigate vaccine-induced inflammation.
• This method successfully enhances protective immunity, suggesting a new paradigm for vaccine formulation.
• The approach holds potential for broad application in the development of safer and more effective vaccines against various pathogens.